Videos

Richard S. Finn, MD, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma.

Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.

Andrew Turk, MD, discusses the main factors that can be used to determine whether a patient presenting with thyroid cancer has an indolent form of the disease or a more aggressive thyroid cancer.

Prostate Cancer

Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.

Timothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.

Tanya Siddiqi, MD, discusses how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase III ASCEND trial.

Relapsed ALK-Rearranged NSCLC

Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br /> &nbsp;

Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with&nbsp;<em>EGFR</em>-positive non&ndash;small cell lung cancer.